| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | Arroyo Grande |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | Berkeley |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | Beverly Hills |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune, Inc. | Beverly Hills |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | Cerritos |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | Coronado |
| A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer | Phase 1 | Bayer | Duarte |
| A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer | — | City of Hope Medical Center | Duarte |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | Phase 1 | SEED Therapeutics, Inc. | Duarte |
| A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors | Phase 1/2 | BeOne Medicines | Duarte |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | Duarte |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | Phase 1 | AbbVie | Duarte |
| A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | Phase 1/2 | Bristol-Myers Squibb | Duarte |
| An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer | — | City of Hope Medical Center | Duarte |
| Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer | Phase 2 | City of Hope Medical Center | Duarte |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | Duarte |
| Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases | — | City of Hope Medical Center | Duarte |
| GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC | Phase 1/2 | Eureka Therapeutics Inc. | Duarte |
| Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study) | — | City of Hope Medical Center | Duarte |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | Duarte |
| Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Phase 1 | AbbVie | Duarte |
| Distance-Based Exercise to Preserve Function and Prevent Disability | N/A | Alliance for Clinical Trials in Oncology | Dublin |
| Multi-analyte Blood Test Clinical Trial | — | Helio Genomics | Escondido |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | — | Fresenius Kabi | Fountain Valley |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | Fullerton |
| Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma | Phase 1 | Shanghai Henlius Biotech | Glendale |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | Irvine |
| Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body. | Phase 1/2 | Pfizer | Irvine |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | Phase 1/2 | National Cancer Institute (NCI) | Irvine |
| Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure | Phase 2 | CatalYm GmbH | Irvine |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | La Jolla |
| A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 | — | Replimune, Inc. | La Jolla |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | La Jolla |
| BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases | Phase 2 | Darren Sigal, MD | La Jolla |
| CapTemY90 for Grade 2/3 NET Liver Metastases | Phase 2 | Abramson Cancer Center at Penn Medicine | La Jolla |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | La Jolla |
| Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | Phase 1 | BioEclipse Therapeutics | La Jolla |
| Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer | N/A | University of California, San Diego | La Jolla |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | Long Beach |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | Long Beach |
| A First in Human Study of PLT012 in Participants With Solid Tumor Cancers | Phase 1 | Pilatus Biosciences Inc | Los Angeles |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | Los Angeles |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | Los Angeles |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | Los Angeles |
| A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 1/2 | Daiichi Sankyo | Los Angeles |
| CREO - Microwave Ablation Feasibility Study | N/A | Banner Health | Los Angeles |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | Los Angeles |
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Phase 1 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Los Angeles |
| ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma | Phase 1/2 | Eureka Therapeutics Inc. | Los Angeles |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | Los Angeles |
| Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver) | N/A | Johns Hopkins University | Los Angeles |
| Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots | — | University of Southern California | Los Angeles |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | Los Angeles |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | Los Angeles |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Phase 1 | Tyra Biosciences, Inc | Los Angeles |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | Los Angeles |
| Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases | Phase 2 | Kamya Sankar | Los Angeles |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | Los Angeles |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | N/A | Cedars-Sinai Medical Center | Los Angeles |
| Early Detection of Advanced Adenomas and Colorectal Cancer | — | City of Hope Medical Center | Monrovia |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Phase 2 | University of California, Irvine | Orange |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | Phase 2 | Teclison Ltd. | Orange |
| Patient-Derived Xenografts to Reduce Cancer Health Disparities | — | University of California, Davis | Orange |
| Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | N/A | University of California, Irvine | Orange |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | Phase 2 | University of California, Irvine | Orange |
| Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | Phase 2 | University of California, Irvine | Orange |
| Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC | Phase 1/2 | RayzeBio, Inc. | Orange |
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Phase 2 | Teclison Ltd. | Orange |
| Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients | — | University of California, San Diego | Palo Alto |
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | Phase 1/2 | Teclison Ltd. | Palo Alto |
| Intra-procedural Spectral CT for Image-guided Embolization and Ablation in Interventional Oncology | — | Palo Alto Veterans Institute for Research | Palo Alto |
| Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90 | — | Palo Alto Veterans Institute for Research | Palo Alto |
| REGULUS: MRI-guided Adaptive SABR for Liver Cancers | Phase 2 | Stanford University | Palo Alto |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | Palo Alto |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Phase 1 | Exelixis | Palo Alto |
| The Vanguard Study: Testing a New Way to Screen for Cancer | N/A | National Cancer Institute (NCI) | Pleasanton |
| Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer | — | Helio Genomics | Redondo Beach |
| A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment | Phase 1 | AstraZeneca | Rialto |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | San Diego |
| 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer | Phase 1 | University of California, San Francisco | San Francisco |
| A Multicenter Cancer Biospecimen Collection Study | — | Cofactor Genomics, Inc. | San Francisco |
| A Study of ZW251 in Participants With Advanced Solid Tumors | Phase 1 | Zymeworks BC Inc. | San Francisco |
| Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | Phase 2 | Allison O'Neill, MD | San Francisco |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma | Phase 2 | Mary Feng, MD | San Francisco |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | N/A | University of California, San Francisco | San Francisco |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | Santa Monica |
| PSMA PET for the Staging and Management of Hepatocellular Carcinoma | — | VA Office of Research and Development | West Los Angeles |